Pfizer has said it plans to file for full US approval of its experimental coronavirus vaccine by April next year , even as their vaccine awaits emergency use authorisation by the US Food and Drug Administration ( FDA ) . 
The remarks were made by William Gruber , senior vice president of Pfizer vaccine clinical research and development , at a meeting of independent FDA advisers that are weighing emergency authorisation of the vaccine developed with German partner Bio NTech . 
